Experience

Limula

• Switzerland
• Biotechnology Research
• 1 - 100 Employee

• Independent Non-Executive Director

  • 2022 - Present

  Financing, governance setup and partnering strategy Financing, governance setup and partnering strategy



Kupando GmbH

• Germany
• Biotechnology Research

• Chairman of the Board

  • 2021 - Present

  Development and partnering strategy Development and partnering strategy



Amoéba

• United Kingdom
• Food and Beverage Services
• 1 - 100 Employee

• Independent Non-Executive Director - Chair of the Remuneration Committee

  • 2021 - Present

  Chairman of the Remuneration Committee Corporate strategy, development of human health applications, launch planning for approved biocide and biocontrol solutions Chairman of the Remuneration Committee Corporate strategy, development of human health applications, launch planning for approved biocide and biocontrol solutions



CanSino Biologics Inc.康希诺生物

• Biotechnology Research
• 1 - 100 Employee

• Executive Vice President Portfolio Strategy & Supranational Affairs - Managing Director Europe

  • Jan 2020 - Present

  Setup of the worldwide network of partners to commercialize the vaccines of the company, including the SARS-CoV-2 candidate, perform the relevant clinical trials through licensing-out deals, potentially involving technology transfers, resulting in several hundred million USD of revenue (actual number confidential) Piloting of portfolio strategy and prioritization Interface with supranational organizations (WHO, GAVI, UNICEF, etc.) Setup of the worldwide network of partners to commercialize the vaccines of the company, including the SARS-CoV-2 candidate, perform the relevant clinical trials through licensing-out deals, potentially involving technology transfers, resulting in several hundred million USD of revenue (actual number confidential) Piloting of portfolio strategy and prioritization Interface with supranational organizations (WHO, GAVI, UNICEF, etc.)



MYCB1 Group B.V.

• Netherlands
• Hospitals and Health Care
• 1 - 100 Employee

• Chairman of the Board

  • 2020 - Present

  Setup of the corporate quality procedures and GMP manufacturing in preparation for a near-term IPO Go-to-market strategy including health economic rationale and compliance with pharmaceutical regulations Setup of the corporate quality procedures and GMP manufacturing in preparation for a near-term IPO Go-to-market strategy including health economic rationale and compliance with pharmaceutical regulations



Health Technology Holdings

• Health, Wellness & Fitness
• 1 - 100 Employee

• Chairman of the Board

  • 2020 - Present

  Investment portfolio management and due diligence on new opportunities Participation in series C of Univercells and other early-stage medtech and biotech financing Investment portfolio management and due diligence on new opportunities Participation in series C of Univercells and other early-stage medtech and biotech financing



UNIVERCELLS

• Belgium
• Biotechnology Research
• 1 - 100 Employee

• Independent Non-Executive Director - Executive Chairman of Quantoom Biosciences

  • 2018 - Present

  Executive Chairman of Quantoom Biosciences (vaccine division of Univercells) Series A extension initiative, brought a novel investor and invested personally in the company Portfolio strategy and business development, concluding several licensing-out deals Series B financing and joined the Board as NED at the completion of the Series B Business plan and setup of the Vaccines affiliate, in the context of the preparation of the Series C Series D financing Executive Chairman of Quantoom Biosciences (vaccine division of Univercells) Series A extension initiative, brought a novel investor and invested personally in the company Portfolio strategy and business development, concluding several licensing-out deals Series B financing and joined the Board as NED at the completion of the Series B Business plan and setup of the Vaccines affiliate, in the context of the preparation of the Series C Series D financing



Barinthus Biotherapeutics

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• Independent Non-Executive Director - Chair Governance Committee - Member Finance Committee

  • 2017 - Present

  Chairman of the Nomination & Governance Committee Member of the Finance & Audit Committee Supporting the development strategy, fund raising and business development initiatives Set up of Vaccitech affiliate in Australia Portfolio strategy across targeted fields, from infectious diseases to immuno-oncology NASDAQ IPO (April 2021) Chairman of the Nomination & Governance Committee Member of the Finance & Audit Committee Supporting the development strategy, fund raising and business development initiatives Set up of Vaccitech affiliate in Australia Portfolio strategy across targeted fields, from infectious diseases to immuno-oncology NASDAQ IPO (April 2021)


MassChallenge Switzerland
• Switzerland
• Venture Capital and Private Equity Principals
• 1 - 100 Employee
• Expert - Mentor - Judge

  • 2017 - Present


MRGN Advisors

• Switzerland
• Biotechnology Research

• Chief Executive Officer & Founder

  • Jan 2015 - Present

  Portfolio strategy, commercial and market access development, partnering, corporate policy and investment advisory to CEOs, supervisory boards and investors in pharma, biologicals, vaccines, med tech and healthcare IT. http://www.mrgnadvisors.com/ Portfolio strategy, commercial and market access development, partnering, corporate policy and investment advisory to CEOs, supervisory boards and investors in pharma, biologicals, vaccines, med tech and healthcare IT. http://www.mrgnadvisors.com/



Merieux Equity Partners

• France
• Venture Capital and Private Equity Principals
• 1 - 100 Employee

• Regional Partner - Senior Advisor

  • 2014 - Present

  Identified opportunities for capital development investments in Switzerland (segments: Medical Technology, In Vitro Diagnostics, e-Health, Nutraceuticals) and established the fund relationships with private equity stakeholders Identified opportunities for capital development investments in Switzerland (segments: Medical Technology, In Vitro Diagnostics, e-Health, Nutraceuticals) and established the fund relationships with private equity stakeholders



Eurocine Vaccines

• Sweden
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Chairman of the Board

  • 2013 - Present

  Vision, strategy, and execution to achieve and sustain partnering excellence at this publicly listed, clinical stage company dedicated to the development of nasal vaccines Product development process through to Proof of Concept, followed by active efforts to secure licensing agreements with strategic partners to achieve co-development deals towards commercial launch Successful share issues in 2015, 2016, 2019, 2020, 2021 and 2022 Strategic pivot towards novel preclinical assets Vision, strategy, and execution to achieve and sustain partnering excellence at this publicly listed, clinical stage company dedicated to the development of nasal vaccines Product development process through to Proof of Concept, followed by active efforts to secure licensing agreements with strategic partners to achieve co-development deals towards commercial launch Successful share issues in 2015, 2016, 2019, 2020, 2021 and 2022 Strategic pivot towards novel preclinical assets



Adiposs

• Switzerland
• Biotechnology Research

• Chairman of the Board

  • Jan 2020 - Jun 2023

  Setup of corporate governance, clinical development plan and fundraising Setup of corporate governance, clinical development plan and fundraising



Theradiag

• France
• Biotechnology
• 1 - 100 Employee

• Chairman of the Board

  • 2012 - Mar 2023

  Chairman of the Remuneration Committee Preparations and requirements to successfully launch the IPO, reaching the highest share price in the planned bracket and surpassing capital expectations by 40% (€8.2m raised, global demand of €15.1m, share price set at the upper end of the offering range at €5.80) Trusted advisor to company leadership, reviewing and approving all business growth strategy, including penetration into global markets, the acquisition of Prestizia, and the installation… Show more Chairman of the Remuneration Committee Preparations and requirements to successfully launch the IPO, reaching the highest share price in the planned bracket and surpassing capital expectations by 40% (€8.2m raised, global demand of €15.1m, share price set at the upper end of the offering range at €5.80) Trusted advisor to company leadership, reviewing and approving all business growth strategy, including penetration into global markets, the acquisition of Prestizia, and the installation of internal controls P&L management and corporate finance as a member of the Audit Committee Hiring of a new CEO Management of the take over by Biosynex Show less Chairman of the Remuneration Committee Preparations and requirements to successfully launch the IPO, reaching the highest share price in the planned bracket and surpassing capital expectations by 40% (€8.2m raised, global demand of €15.1m, share price set at the upper end of the offering range at €5.80) Trusted advisor to company leadership, reviewing and approving all business growth strategy, including penetration into global markets, the acquisition of Prestizia, and the installation… Show more Chairman of the Remuneration Committee Preparations and requirements to successfully launch the IPO, reaching the highest share price in the planned bracket and surpassing capital expectations by 40% (€8.2m raised, global demand of €15.1m, share price set at the upper end of the offering range at €5.80) Trusted advisor to company leadership, reviewing and approving all business growth strategy, including penetration into global markets, the acquisition of Prestizia, and the installation of internal controls P&L management and corporate finance as a member of the Audit Committee Hiring of a new CEO Management of the take over by Biosynex Show less

• Independent Non-Executive Director

  • 2018 - 2019

  Chair of the Remuneration and Assessment Committee Supported the preparation of the IPO prospectus (IPO executed on the Hong Kong stock exchange on 27 March 2019) Chair of the Remuneration and Assessment Committee Supported the preparation of the IPO prospectus (IPO executed on the Hong Kong stock exchange on 27 March 2019)



Virometix AG

• Switzerland
• Biotechnology Research
• 1 - 100 Employee

• Chairman of the Board

  • 2017 - 2019

  Driving the Series A financing round: oversubscribed to CHF 6.2m Aligning the corporate strategy for the selection of development candidates and of industrial partners Driving the Series A financing round: oversubscribed to CHF 6.2m Aligning the corporate strategy for the selection of development candidates and of industrial partners



Alma Biotherapeutics

• France
• Biotechnology Research
• 1 - 100 Employee

• Independent Non-Executive Director

  • 2017 - 2018

  Series A financing Fine-tuning the value story and preparing the company for the transition from preclinical to clinical phase Series A financing Fine-tuning the value story and preparing the company for the transition from preclinical to clinical phase



AJ Biologics

• Ireland
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer

  • 2014 - 2016

  Multimillion-dollar acquisition of the vaccine production and commercialization business of the Statens Serum Institute by AJ Pharma Advised AJ Vaccines on partnerships and innovation strategy Capital investment (USD 50 million), portfolio and manufacturing strategy, and business development and partnering activities, including 3 product licensing-in deals Vision and positioning of AJ Biologics as an emerging force in the vaccine market, and a portfolio of vaccines through… Show more Multimillion-dollar acquisition of the vaccine production and commercialization business of the Statens Serum Institute by AJ Pharma Advised AJ Vaccines on partnerships and innovation strategy Capital investment (USD 50 million), portfolio and manufacturing strategy, and business development and partnering activities, including 3 product licensing-in deals Vision and positioning of AJ Biologics as an emerging force in the vaccine market, and a portfolio of vaccines through multi-country licensing-in (ASEAN and MENA regions) and co-development agreements (partners in France, China and Taiwan) Built a team of seasoned executives with vaccine experience and entrepreneurial spirit Show less Multimillion-dollar acquisition of the vaccine production and commercialization business of the Statens Serum Institute by AJ Pharma Advised AJ Vaccines on partnerships and innovation strategy Capital investment (USD 50 million), portfolio and manufacturing strategy, and business development and partnering activities, including 3 product licensing-in deals Vision and positioning of AJ Biologics as an emerging force in the vaccine market, and a portfolio of vaccines through… Show more Multimillion-dollar acquisition of the vaccine production and commercialization business of the Statens Serum Institute by AJ Pharma Advised AJ Vaccines on partnerships and innovation strategy Capital investment (USD 50 million), portfolio and manufacturing strategy, and business development and partnering activities, including 3 product licensing-in deals Vision and positioning of AJ Biologics as an emerging force in the vaccine market, and a portfolio of vaccines through multi-country licensing-in (ASEAN and MENA regions) and co-development agreements (partners in France, China and Taiwan) Built a team of seasoned executives with vaccine experience and entrepreneurial spirit Show less



CEGEDIM

• France
• IT Services and IT Consulting
• 700 & Above Employee

• Chief Marketing Officer

  • 2013 - 2014

  Talent development initiatives to improve performance across a team of 50+ marketing professionals Evolution of marketing strategy targeting Life Science companies for all Cegedim businesses supporting €453m in Revenues and €63m of EBITDA in Fiscal 2013, growing EBITDA on Revenue by 0.6% Product and portfolio strategy to identify areas of opportunity and improvement, recommending innovative, targeted go-to market approaches and customer value propositions and designing integrated… Show more Talent development initiatives to improve performance across a team of 50+ marketing professionals Evolution of marketing strategy targeting Life Science companies for all Cegedim businesses supporting €453m in Revenues and €63m of EBITDA in Fiscal 2013, growing EBITDA on Revenue by 0.6% Product and portfolio strategy to identify areas of opportunity and improvement, recommending innovative, targeted go-to market approaches and customer value propositions and designing integrated solutions supported by consulting selling Marketing planning cycle across multiple metrics, including business intelligence, market research, product strategy, client value proposition, and the execution of pricing and planning Show less Talent development initiatives to improve performance across a team of 50+ marketing professionals Evolution of marketing strategy targeting Life Science companies for all Cegedim businesses supporting €453m in Revenues and €63m of EBITDA in Fiscal 2013, growing EBITDA on Revenue by 0.6% Product and portfolio strategy to identify areas of opportunity and improvement, recommending innovative, targeted go-to market approaches and customer value propositions and designing integrated… Show more Talent development initiatives to improve performance across a team of 50+ marketing professionals Evolution of marketing strategy targeting Life Science companies for all Cegedim businesses supporting €453m in Revenues and €63m of EBITDA in Fiscal 2013, growing EBITDA on Revenue by 0.6% Product and portfolio strategy to identify areas of opportunity and improvement, recommending innovative, targeted go-to market approaches and customer value propositions and designing integrated solutions supported by consulting selling Marketing planning cycle across multiple metrics, including business intelligence, market research, product strategy, client value proposition, and the execution of pricing and planning Show less



Sanofi

• France
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Vice President, Member of the Executive Committee

  • 2009 - 2013

  Directed global marketing, business intelligence, pricing, and market access, with authority over a team of 60 Directed all aspects of strategic planning, management of a portfolio of commercial projects, and global supply management, for consolidated company P&L (Sales of €3.6b and Business Operating Income of €1.1b in Fiscal 2012) and shared accountability over industrial capital investment (€400m per annum) and R&D portfolio prioritization Eliminated over €10m both in 2010 and 2011 in… Show more Directed global marketing, business intelligence, pricing, and market access, with authority over a team of 60 Directed all aspects of strategic planning, management of a portfolio of commercial projects, and global supply management, for consolidated company P&L (Sales of €3.6b and Business Operating Income of €1.1b in Fiscal 2012) and shared accountability over industrial capital investment (€400m per annum) and R&D portfolio prioritization Eliminated over €10m both in 2010 and 2011 in distribution costs through the creation of an integrated supply chain Successfully redesigned the Global Marketing organization and the Franchise Planning process, transitioning operational matters, such as sales and marketing, pricing, and product communications, to commercial operations Spearheaded management of novel vaccines, life cycle management projects, process improvements and new product launches that included Menactra (quadravalent Meninge conjugate), Adacel (adult pertussis booster), Intanza (intra-dermal flu) and the pre-launches of Imojev (Japanese encephalitis), Hexaxim (hexavalent pediatric combination), Clostridium difficile vaccines, and the integration of Shantha Biotechnics (as a director at the board) Sponsored the long-term strategy for China and launched a full spectrum of supporting initiatives Show less Directed global marketing, business intelligence, pricing, and market access, with authority over a team of 60 Directed all aspects of strategic planning, management of a portfolio of commercial projects, and global supply management, for consolidated company P&L (Sales of €3.6b and Business Operating Income of €1.1b in Fiscal 2012) and shared accountability over industrial capital investment (€400m per annum) and R&D portfolio prioritization Eliminated over €10m both in 2010 and 2011 in… Show more Directed global marketing, business intelligence, pricing, and market access, with authority over a team of 60 Directed all aspects of strategic planning, management of a portfolio of commercial projects, and global supply management, for consolidated company P&L (Sales of €3.6b and Business Operating Income of €1.1b in Fiscal 2012) and shared accountability over industrial capital investment (€400m per annum) and R&D portfolio prioritization Eliminated over €10m both in 2010 and 2011 in distribution costs through the creation of an integrated supply chain Successfully redesigned the Global Marketing organization and the Franchise Planning process, transitioning operational matters, such as sales and marketing, pricing, and product communications, to commercial operations Spearheaded management of novel vaccines, life cycle management projects, process improvements and new product launches that included Menactra (quadravalent Meninge conjugate), Adacel (adult pertussis booster), Intanza (intra-dermal flu) and the pre-launches of Imojev (Japanese encephalitis), Hexaxim (hexavalent pediatric combination), Clostridium difficile vaccines, and the integration of Shantha Biotechnics (as a director at the board) Sponsored the long-term strategy for China and launched a full spectrum of supporting initiatives Show less



BioAlliance Pharma

• Chief Operating Officer

  • 2008 - 2009

  Expanded operations globally, securing new partnerships and funding (e.g. €6.4m from the French state innovation agency) and executing a partnership with PAR Pharmaceuticals in the US (worth over €20m in milestone payments) Designed pricing, commercialization and risk management strategy for Bio Pharma alliances, transitioning operations towards a pan European partnership in oncology/supportive care, and reacquiring the rights of Loramyc in Europe Expanded operations globally, securing new partnerships and funding (e.g. €6.4m from the French state innovation agency) and executing a partnership with PAR Pharmaceuticals in the US (worth over €20m in milestone payments) Designed pricing, commercialization and risk management strategy for Bio Pharma alliances, transitioning operations towards a pan European partnership in oncology/supportive care, and reacquiring the rights of Loramyc in Europe



Schering Plough

• Belgium
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Director Primary Care Operations

  • 2006 - 2008

  Met the challenge of directing primary care operations worth €270m in sales and €145m in contribution, with oversight of 3 marketing teams, a dedicated hospital sales team, and 4 retail sales forces in metropolitan France, as well as retail and hospital sales teams in French Overseas Territories, totaling over 530 staff members Reached €161m in sales by March 2008 for Ezetrol (ezetimibe) and Inegy (ezetimibe/simvastatin) in the treatment of dyslipidemia, effectively managing a partnership… Show more Met the challenge of directing primary care operations worth €270m in sales and €145m in contribution, with oversight of 3 marketing teams, a dedicated hospital sales team, and 4 retail sales forces in metropolitan France, as well as retail and hospital sales teams in French Overseas Territories, totaling over 530 staff members Reached €161m in sales by March 2008 for Ezetrol (ezetimibe) and Inegy (ezetimibe/simvastatin) in the treatment of dyslipidemia, effectively managing a partnership with Merck at the national level Safeguarded a €76m business by introducing a pricing negotiation strategy for Aerius with the Health Authorities • Contributed to the success of 7 global task forces dedicated to expanding primary care product franchises, improving the launch preparedness, designing the market access strategy, and developing a leader behaviors training program Show less Met the challenge of directing primary care operations worth €270m in sales and €145m in contribution, with oversight of 3 marketing teams, a dedicated hospital sales team, and 4 retail sales forces in metropolitan France, as well as retail and hospital sales teams in French Overseas Territories, totaling over 530 staff members Reached €161m in sales by March 2008 for Ezetrol (ezetimibe) and Inegy (ezetimibe/simvastatin) in the treatment of dyslipidemia, effectively managing a partnership… Show more Met the challenge of directing primary care operations worth €270m in sales and €145m in contribution, with oversight of 3 marketing teams, a dedicated hospital sales team, and 4 retail sales forces in metropolitan France, as well as retail and hospital sales teams in French Overseas Territories, totaling over 530 staff members Reached €161m in sales by March 2008 for Ezetrol (ezetimibe) and Inegy (ezetimibe/simvastatin) in the treatment of dyslipidemia, effectively managing a partnership with Merck at the national level Safeguarded a €76m business by introducing a pricing negotiation strategy for Aerius with the Health Authorities • Contributed to the success of 7 global task forces dedicated to expanding primary care product franchises, improving the launch preparedness, designing the market access strategy, and developing a leader behaviors training program Show less



Drug Abuse Sciences

• United States
• Hospitals and Health Care

• Chief Executive Officer

  • 2006 - 2006

  Raised €5m, leading a road show to showcase the company’s potential to private investors Supported the divestment of assets Raised €5m, leading a road show to showcase the company’s potential to private investors Supported the divestment of assets



Bristol Myers Squibb

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Vice President Hospital Operations

  • 2004 - 2006

  Newly created role with a mandate to assemble multiple disparate business units and support functions into a cohesive, efficient, and productive new organization Directed 180+ staff members in hospital operations, €330m in sales and €245m in contribution, across 3 business units (Virology, Oncology-Pain, Neurosciences) and 2 support departments (Customer Marketing, Commercial Operations) Successful launched of Abilify (aripiprazole, schizophrenia); executed pre-launch plans for Baraclude… Show more Newly created role with a mandate to assemble multiple disparate business units and support functions into a cohesive, efficient, and productive new organization Directed 180+ staff members in hospital operations, €330m in sales and €245m in contribution, across 3 business units (Virology, Oncology-Pain, Neurosciences) and 2 support departments (Customer Marketing, Commercial Operations) Successful launched of Abilify (aripiprazole, schizophrenia); executed pre-launch plans for Baraclude (entecavir, hepatitis B), Sprycel (dasatinib, Chronic Myelogenous Leukemia) and Orencia (abatacept, Rheumatoid Arthritis) Managed the JV interface for Abilify to supplement the resources and efforts of the Otsuka team Show less Newly created role with a mandate to assemble multiple disparate business units and support functions into a cohesive, efficient, and productive new organization Directed 180+ staff members in hospital operations, €330m in sales and €245m in contribution, across 3 business units (Virology, Oncology-Pain, Neurosciences) and 2 support departments (Customer Marketing, Commercial Operations) Successful launched of Abilify (aripiprazole, schizophrenia); executed pre-launch plans for Baraclude… Show more Newly created role with a mandate to assemble multiple disparate business units and support functions into a cohesive, efficient, and productive new organization Directed 180+ staff members in hospital operations, €330m in sales and €245m in contribution, across 3 business units (Virology, Oncology-Pain, Neurosciences) and 2 support departments (Customer Marketing, Commercial Operations) Successful launched of Abilify (aripiprazole, schizophrenia); executed pre-launch plans for Baraclude (entecavir, hepatitis B), Sprycel (dasatinib, Chronic Myelogenous Leukemia) and Orencia (abatacept, Rheumatoid Arthritis) Managed the JV interface for Abilify to supplement the resources and efforts of the Otsuka team Show less



Yamanouchi Pharmaceutical Co

• United States
• Biotechnology Research

• General Manager France

  • 2003 - 2004

  Met top line objectives (€62m in Fiscal 2003-04) and EBITA (13% in 2003-04) for the 3rd largest subsidiary of Yamanouchi Europe with 154 employees; measurably improved the capabilities and the effectiveness of resources Designed a merger plan with Fujisawa France, acting as lead negotiator role between Works Council and Union Representatives Launched Vesicare (solifenacin) while leading product and lobbying initiatives for new product development of tamsulosin Contributed additional… Show more Met top line objectives (€62m in Fiscal 2003-04) and EBITA (13% in 2003-04) for the 3rd largest subsidiary of Yamanouchi Europe with 154 employees; measurably improved the capabilities and the effectiveness of resources Designed a merger plan with Fujisawa France, acting as lead negotiator role between Works Council and Union Representatives Launched Vesicare (solifenacin) while leading product and lobbying initiatives for new product development of tamsulosin Contributed additional service and expertise as an appointed member of the Economic Committee and of the Communication Committee of the LEEM (Union Of Pharmaceutical Companies in France) Show less Met top line objectives (€62m in Fiscal 2003-04) and EBITA (13% in 2003-04) for the 3rd largest subsidiary of Yamanouchi Europe with 154 employees; measurably improved the capabilities and the effectiveness of resources Designed a merger plan with Fujisawa France, acting as lead negotiator role between Works Council and Union Representatives Launched Vesicare (solifenacin) while leading product and lobbying initiatives for new product development of tamsulosin Contributed additional… Show more Met top line objectives (€62m in Fiscal 2003-04) and EBITA (13% in 2003-04) for the 3rd largest subsidiary of Yamanouchi Europe with 154 employees; measurably improved the capabilities and the effectiveness of resources Designed a merger plan with Fujisawa France, acting as lead negotiator role between Works Council and Union Representatives Launched Vesicare (solifenacin) while leading product and lobbying initiatives for new product development of tamsulosin Contributed additional service and expertise as an appointed member of the Economic Committee and of the Communication Committee of the LEEM (Union Of Pharmaceutical Companies in France) Show less



Aventis Pasteur

• United States

• Vice President International Marketing

  • 1998 - 2003

  Successfully debuted pediatric vaccines while securing new commercialization models for flu vaccines, driving a growth in net sales from €304m to €448m from 1998 to 2002, and a +23% CAGR in Operating Profit Delivered gains in productivity and effectiveness through the implementation of a renewed business planning process, incorporating Strategic Profiling, Country-Specific Strategic Plans/Operating Plans, a Medical & Marketing Action Plan Created savings of €15~20m per annum by improved… Show more Successfully debuted pediatric vaccines while securing new commercialization models for flu vaccines, driving a growth in net sales from €304m to €448m from 1998 to 2002, and a +23% CAGR in Operating Profit Delivered gains in productivity and effectiveness through the implementation of a renewed business planning process, incorporating Strategic Profiling, Country-Specific Strategic Plans/Operating Plans, a Medical & Marketing Action Plan Created savings of €15~20m per annum by improved Manufacturing, Medical and Regulatory processes Lead the Polio Life Cycle Team to formulate a global strategy towards the eradication of poliomyelitis, working in concert with the World Health Organization and UNICEF Managed 96 marketing executives within affiliates and 33 marketing staff members at AvP International headquarters Show less Successfully debuted pediatric vaccines while securing new commercialization models for flu vaccines, driving a growth in net sales from €304m to €448m from 1998 to 2002, and a +23% CAGR in Operating Profit Delivered gains in productivity and effectiveness through the implementation of a renewed business planning process, incorporating Strategic Profiling, Country-Specific Strategic Plans/Operating Plans, a Medical & Marketing Action Plan Created savings of €15~20m per annum by improved… Show more Successfully debuted pediatric vaccines while securing new commercialization models for flu vaccines, driving a growth in net sales from €304m to €448m from 1998 to 2002, and a +23% CAGR in Operating Profit Delivered gains in productivity and effectiveness through the implementation of a renewed business planning process, incorporating Strategic Profiling, Country-Specific Strategic Plans/Operating Plans, a Medical & Marketing Action Plan Created savings of €15~20m per annum by improved Manufacturing, Medical and Regulatory processes Lead the Polio Life Cycle Team to formulate a global strategy towards the eradication of poliomyelitis, working in concert with the World Health Organization and UNICEF Managed 96 marketing executives within affiliates and 33 marketing staff members at AvP International headquarters Show less



SYNTHELABO PHARMA SA

• Marketing Director USA-Canada-Japan | CNS Group Product Manager

  • 1990 - 1998

  Shepherded Ambien (zolpidem) to capture the lead market share position in less than one year in the United States, exceeding $400m in value in the fifth year after launch; Led Kerlong (betaxolol) to capture 5th place in the Japanese beta-blocking market, reaching Yen 7b in sales in the fifth year Overall, the USA-Canada-Japan business unit generated 26% of consolidated sales and 41% of consolidated profits Established the medical-marketing processes with the Medical Directors and the R&D… Show more Shepherded Ambien (zolpidem) to capture the lead market share position in less than one year in the United States, exceeding $400m in value in the fifth year after launch; Led Kerlong (betaxolol) to capture 5th place in the Japanese beta-blocking market, reaching Yen 7b in sales in the fifth year Overall, the USA-Canada-Japan business unit generated 26% of consolidated sales and 41% of consolidated profits Established the medical-marketing processes with the Medical Directors and the R&D units and led the creation of the Synthelabo marketing teams in the USA and in Japan; directly managed marketing teams in Japan and the US Successfully preserved Stilnox from being engulfed in a product crisis, when a sister product containing an active ingredient of the same chemical class was pulled from the market due to lethal side effects Launched Stilnox in Germany/Spain and managed co-marketing partners in both countries Show less Shepherded Ambien (zolpidem) to capture the lead market share position in less than one year in the United States, exceeding $400m in value in the fifth year after launch; Led Kerlong (betaxolol) to capture 5th place in the Japanese beta-blocking market, reaching Yen 7b in sales in the fifth year Overall, the USA-Canada-Japan business unit generated 26% of consolidated sales and 41% of consolidated profits Established the medical-marketing processes with the Medical Directors and the R&D… Show more Shepherded Ambien (zolpidem) to capture the lead market share position in less than one year in the United States, exceeding $400m in value in the fifth year after launch; Led Kerlong (betaxolol) to capture 5th place in the Japanese beta-blocking market, reaching Yen 7b in sales in the fifth year Overall, the USA-Canada-Japan business unit generated 26% of consolidated sales and 41% of consolidated profits Established the medical-marketing processes with the Medical Directors and the R&D units and led the creation of the Synthelabo marketing teams in the USA and in Japan; directly managed marketing teams in Japan and the US Successfully preserved Stilnox from being engulfed in a product crisis, when a sister product containing an active ingredient of the same chemical class was pulled from the market due to lethal side effects Launched Stilnox in Germany/Spain and managed co-marketing partners in both countries Show less



ICI PHARMA

• France
• Retail
• 1 - 100 Employee

• Product Manager Anesthetics

  • 1988 - 1990

  Increased product portfolio revenue by 400%, tripling the sales of Diprivan (propofol) in two years (from 35 to 102 million FF) and successfully launching new indications and presentations, bringing France to the second position in value (behind the US) Introduced a renewed 3 Year Strategic Plan and a specific task force to test the new promotional materials Increased product portfolio revenue by 400%, tripling the sales of Diprivan (propofol) in two years (from 35 to 102 million FF) and successfully launching new indications and presentations, bringing France to the second position in value (behind the US) Introduced a renewed 3 Year Strategic Plan and a specific task force to test the new promotional materials